MedTrace Logo

Thoracic Paravertebral Blocks Using a Combination of Ropivacaine and Dexmedetomidine

NCT03677115 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-11-12

No results posted yet for this study

Summary

The investigators designed a study to assess whether thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine prolong nerve block duration.

Conditions

  • Thoracic Paravertebral Blocks

Interventions

DRUG

Dexmedetomidine

combination of ropivacaine and dexmedetomidine 20 ug every time

Sponsors & Collaborators

  • China Medical University, China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2023-03-30
Completion
2023-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03677115 on ClinicalTrials.gov